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Abstract
Background: Intertrigo in the large skin folds is a common problem. There is a plethora of treatments, but a lack
of evidence about their efficacy. A nursing guideline on this matter had to be updated and broadened in scope to
other health care professionals.
Methods: A systematic review was performed. Thirteen databases were sensitively searched, supplemented by
reference tracking and forward citation searches. All types of empirical research relating to the prevention or
treatment of intertrigo were included. Study selection, assessment of bias, data-extraction and analysis were done
by two independent review-authors.
Results: Sixty-eight studies fulfilled the inclusion criteria. Only 4 studies were RCTs and even these had a
considerable risk of bias. Study populations were generally small.
No studies were found about the prevention of intertrigo. The therapies concerned mostly the topical application
of antimycotics, corticosteroids, antibiotics, antiseptics or a combination of these. Besides these pharmaceutical
interventions, surgical breast reduction was also studied. Although most study-authors were positive, we could not
draw firm conclusions about any of the pharmaceutical interventions. Even patients that received placebo interven-
tion showed improvement. There is weak evidence that reduction mammaplasty may be helpful to treat inframam-
mary intertrigo. All research found had considerable risk of bias, prohibiting firm conclusions.
Conclusions: There is no evidence at all about the prevention of intertrigo and there is no firm evidence about its
treatment. Well designed studies are needed.
Background
Intertrigo is an inflammatory dermatosis involving body
folds that develops through friction of skin to skin and
is influenced by moist conditions. Intertrigo is found
primarily in the inframammary, inguinal, abdominal and
perianal skin folds. Besides these large skin folds, inter-
trigo may also affect minor skin folds. Intertrigo has
been defined as ‘an erythematous eruption in a skin
fold, caused by warmth, moisture and chafing; it occurs
most often in the skin folds under the breasts and in
the groin’ [1,2] or as ‘a cutaneous inflammatory process
on opposing skin surfaces’ [3] or ‘an inflammatory der-
matosis involving body folds’ [4].
The moist damaged skin can become secondary
infected by bacteria or yeast and fungi. Visual symptoms
of intertrigo are redness in mirror format and moist
skin. Patients may complain of itching, burning feeling,
pain and odor [1,2,5].
Prevalence of intertrigo in the large skin folds varies
from 6% in hospital patients to 17% in nursing home
clients and 20% in home care patients [6-12]. There are,
to our knowledge, no figures about the prevalence of
intertrigo in the general population, largely due to the
fact that intertrigo has no specific ICD-10 or ICPC-
score. Also there is overlap in medical taxonomies
between intertrigo, dermatomycoses and bacterial skin
infections.
A nursing guideline on the prevention and treatment
of intertrigo was published in the Netherlands in 2004
[13]. For that guideline a systematic review [14] was per-
formed containing references up to June 2002 and lim-
ited to interventions in the nursing domain. The review
revealed that there was a plethora of interventions used
but a dearth of well designed studies.
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updated and needed a broader scope, so it could be
used by other health professionals as well. Therefore a
new, updated and broadened systematic review was
required. The aim of this manuscript is to give an over-
view of the evidence for preventing and treating inter-
trigo in the large skin folds of adult patients.
Methods
A systematic review of the relevant international litera-
ture was performed. Two reviewers worked together
during all steps of the review.
The search string ’Intertrigo [MESH] OR intertrig*’ was
used for Pubmed and adapted for the other databases.
The following 13 databases were searched, with no lim-
itations concerning date or language:
1. PUBMED (United States National Library of
Medicine)
2. Embase (Excerpta Medica Database)
3. The Cochrane Library
(Cochrane Database of Systematic Reviews/Database
of Abstracts of Reviews of Effects/Cochrane Central
Register of Controlled Trials/Cochrane Methodology
Register/Health Technology Assessment Database/
NHS Economic Evaluation Database)
4. CINAHL (Cumulative Index to Nursing and
Allied Health Literature)
5. SCI (Science Citation Index)
(Science Citation Index Expanded/Social Sciences
Citation Index/Arts & Humanities Citation Index)
6. PICARTA (Dutch central library catalogue)
(NCC & OLC)
7. INVERT (Catalogue of Dutch nursing literature)
8. NHS-National Library for Health
9. LILACS (Latin American and Caribbean Health
Sciences Literature)
10. SCIELO (Scientific Electronic Library Online of
Brazilian scientific journals)
11. IMEMR (Index Medicus for the WHO Eastern
Mediterranean Region)
12. AMED (Allied and Alternative MEDicine)
13. CAMbase (Complementary and Alternative
Medicine)
In addition, references from relevant reviews or guide-
lines found during the above search actions were added
to the initial database and a forward search was per-
formed in SCI with the manuscripts that fulfilled the
inclusion criteria. All searches were performed begin
April 2009.
To be eligible for inclusion, the manuscripts had to meet
the following inclusion criteria (in PICO(T)-format):
P atient: Adult patients with (a risk for) intertrigo,
which may or may not be infected. The intertrigo
has to be located in a major skin fold (inframam-
mary, inguinal, perianal, abdominal or axillary) for
the entire or part of the research population
I ntervention: all interventions aimed at the preven-
tion or the treatment of intertrigo
C ontrol: no restrictions
O utcome: the absence/presence of intertrigo or
increase/decrease in intertrigo symptoms, assessed
by either the patient or a health professional
T ype research: all primary research performed in
humans with a sample size >1
Exclusion criteria were research on children, ailments
in minor skin folds (e.g. interdigital), diaper dermatitis,
specific diseases other than intertrigo ((bv. eczema, Hai-
ley-Hailey disease, pemphigus, granuloma, psoriasis,
acanthosis, Darier disease), in vitro research, research
on animals, opinion articles, editorials and letters.
Inclusion criteria were assessed firstly on title and
abstract (if available) and later on the full-text. The
inclusion process was conducted by the two review-
authors, independently of each other. Disagreements
were discussed until consensus was reached.
Following data were extracted
- General (authors, journal, publication date, country,
language)
- Research method (objective, design, analysis)
- Research population (age, gender, setting, sample
size)
- Applied (control) interventions (type, dose, fre-
quency, performer)
- Outcomes (type, instrument, time of measurement,
frequency, assessor)
- Results & conclusions
The data were extracted by the first review-author and
checked by the second.
Data were extracted only for those articles in which
the entire research population consisted of patients with
intertrigo in the large skin folds or, where these patients
formed only part of the research population, for those
articles that gave separate analyses for patients with
intertrigo in large skin folds.
To assess the risk of bias, the included studies were first
divided into comparative or non-comparative studies.
Non-comparative studies were all those that used only a
single treatment arm. The comparative studies were then
further divided into a group where there was no (clear)
randomization applied and a group of studies in which
patients were allocated by randomization (RCTs). Without
further assessment, all non-comparative studies and all
comparative studies without randomization were classified
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assessed on risk of bias with the screening score instru-
ment that was introduced by NICE in 2009 [15]. This
instrument screens for the risk on four types of bias
(’selection bias’, ‘performance bias’, ‘attrition bias’ and
‘detection bias’). For each type three questions have to be
answered and a conclusion formulated of either ‘low risk
of bias’, ‘unclear/unknown risk of bias’ or ‘high risk of
bias’. Studies that scored ‘low risk of bias’ on all four com-
ponents received a total score of ‘low risk’; studies with
‘high risk of bias’ on all 4 components were scored totally
as ‘high risk’ and all other combinations as ‘unclear/
unknown risk of bias’.
Risk of bias assessment was conducted by the two
review-authors, independently of each other and dis-
agreements were discussed until consensus was reached.
For the data-synthesis, studies were first categorized to
prevention or treatment of intertrigo.
The treatments were than further categorized to (one
or more) kind(s) of intervention: antimycotics, corticos-
teroids, antibiotics, antiseptics, combinations, placebo,
surgical and other. For the comparative studies, a dis-
tinction was made between studies in which the inter-
vention was compared to the same product but in
another dose or frequency and studies in which an
intervention was compared to another different inter-
vention (either another therapeutic product, a placebo
product or natural course).
It was planned to perform statistical meta-analysis
with Review Manager 5.0 (risk ratios for dichotomous
outcomes and weighted mean difference for continuous
outcomes and both based on a random effects-model)
on condition that there was enough statistical and clini-
cal homogeneity.
Results
Seach Results and General Characteristics
The initial searches in the various databases yielded
1989 hits (Additional file 1). After eliminating duplicates
1,124 references were left for the inclusion process. All
but 2 databases revealed unique hits.
Initial assessment of the references on title and
abstract resulted in 316 references that were retained
for full-text inclusion assessment. Of these, three could
not be obtained in full-text. After full-text assessment,
136 references were excluded and 177 included.
Of these 177 references, 75 were manuscripts of
empirical research on patients of whom all or some suf-
fered from intertrigo in large skin folds. No studies were
found with a population that received prevention for
intertrigo. The other 102 references were either litera-
ture reviews or guidelines. The references of these were
entered into the initial database and assessed on the
inclusion criteria for this review. This resulted in 62
new references that were not part of the initial database.
Twenty-two of these 62 references fulfilled the inclusion
criteria and were added to the set for data-extraction.
Together with the 75 references from the initial search
and the 22 from the reference tracking we had a set 97
relevant references. All these were than entered into the
Science Citation Index for a forward search to find
manuscripts that referred to one of these 97 references.
This resulted in 58 new references that were assessed
on the inclusion criteria, which meant an additional six
could be added to the set for data-extraction (totaling
103 references).
These 103 references referred to 100 different studies.
Only in 68 studies were separate analyses for intertrigo
in large skin folds presented; in the remainder the inter-
trigo in large skin folds was studied together with other
diseases (e.g. all kind of dermatomycoses) or with other
locations (large skin folds and interdigital ailments taken
together), meaning that no meaningful data extraction
or analyses could be done for this systematic review.
Accordingly, the final set for data extraction and ana-
lyses consisted of 70 references, representing 68 studies
(the two manuscripts of Chapman [16,17] and the two
of Spector [18,19] are respectively discussed as a single
study). The flow of the inclusion process is depicted in
Figure 1.
The 68 included studies date from 1954 up to 2008.
Half of them date from before 1985 and 10% have been
published in the last 5 years. The studies originate from
27 different countries; most are from the USA (16 stu-
dies), France (9 studies) or Germany and the UK (both
6 studies)). The studies were published in 51 different
journals en in 9 different languages (for these the
review-authors sought assistance from colleagues who
master those specific languages).
Research Designs and Risk of Bias
The 68 studies concerned 52 non-comparative and 16
comparative studies. Most of the non-comparative stu-
dies used a post-only design. Of the 16 comparative stu-
dies only four used a randomization procedure to
allocate the patients to the research conditions. These
four RCTs [20-23] were assessed on the risk of bias
with the NICE-instrument [24]. None of the four com-
plied with the criteria to qualify as ‘low-risk on bias’.
The largest problem in these four studies concerned the
absence of valid and reliable instruments and methods
by which outcomes were measured, resulting in high
risk of detection bias. All four RCTs were judged as
‘unclear/unknown risk of bias’. All other studies than
the RCTs were judged as ‘large risk on bias’.
In six of the 16 comparative studies a placebo inter-
vention was used in one of the comparison groups. No
study used natural course for comparison.
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skin folds was rather small (median = 21; mean = 52.7;
sd = 78.9; min-max = 1-406). Due to these small sam-
ples, there is a priori a considerable chance that the stu-
dies could not detect significant differences between
groups.
The scientific quality of the studies was hampered
even more by the fact that almost all the studies mea-
sured their outcomes with self developed instruments
that had unclear psychometric properties.
In addition, outcomes were measured at many differ-
ent moments after the start of therapy, making compari-
sons between studies difficult.
Another methodological problem was that most
papers did not, or not clearly, present the extent to
which the interventions and control conditions were
implemented as was intended, i.e. in regard to dose, fre-
quency or actor. For example, ‘ointment 1 to 4 times a
day’ or ‘for a period of 1 to 4 weeks’ are not clear
descriptions of an intervention. Likewise, potential con-
founding co-interventions, e.g. hygienic care of skin
folds, were generally not described.
The applied statistics in the papers were not always
scientifically sound and accurate. For example, fre-
quencies were sometimes presented for different
groups but not statistically tested for significant differ-
ences; or sometimes patients that did not respond to
their allocated treatment were switched to an alterna-
tive group or dropped from further analysis, and in the
multicentre studies no multi-level analyses were
applied.
Only a minority of the studies declared that there was
an approval from an ethics review committee or that
patients were asked for informed consent. The financing
source was mentioned in only 7 of the 68 studies; in all
cases this involved a pharmaceutical company.
All things considered, this means that almost all of the
68 included studies lacked scientific rigor and all the
results have to be considered with great caution.
Applied Interventions
No study addressed the prevention of intertrigo. All stu-
dies concerned the treatment of existing intertrigo and
mainly the treatment of intertrigo lesions that were
already infected (n = 40). In only three studies was it
explicitly stated that the research concerned intertrigo
that was not yet infected [16,25,26]. In the remaining
studies the phase/severity of the intertrigo was not clear.
A large variety of therapeutic interventions was
applied, with the majority consisting of some kind of
topical pharmaceutical treatment (antimycotics, antibio-
tics, antiseptics, corticosteroids or a combination of
these); and in some studies a surgical intervention was
employed (Additional file 2).
All therapeutic interventions concerned topical appli-
cation except for three studies [23,27,28] in which anti-
mycotics were given orally. Within the main categories
many different products were used and also in various
doses, varying frequencies and for varying lengths of
time.
Outcome Measures
The outcome measures applied in the studies can be
roughly categorized into (degree of) healing, (decrease
in) symptoms (number and/or severity), and tolerance
and adverse effects of products
These outcome measures were operationalized in
many ways, measured by various (mostly self-developed)
instruments and assessed for instance in some studies
by laboratory testing, or by physicians, and in other by
patients, and measured at different moments. The
(degree of) healing was the most frequently used pri-
mary outcome.
Data Synthesis
The large variety of interventions, even within a specific
category, and the large variety in outcome measures and
measurements caused to large heterogeneity to attempt
statistically pooling of results. Therefore results are pre-
sented below and in the Additional files 3, 4 and 5 only
in a merely descriptive fashion.
Antimycotics
Antimycotics were used in 38 studies [20-23,27-60]. In
25 studies the antimycotic was used as a sole interven-
tion; in the other cases the antimycotic was part of a
combination. Only the studies with the antimycotic as a
sole intervention are discussed here. Ten studies were
comparative, either with the same product but in differ-
ent form or using another way of administration (n =
4), or with another therapy (n = 4), or with a placebo-
intervention (n = 5). Randomization was used in three
of these 10 comparative studies.
The mean sample size of patients with intertrigo in
the large skin folds in the 25 antimycotic studies was
34.7 patients (sd 59.2, min-max 1-245, median 18).
The applied antimycotics were categorized according to
the Dutch Pharmacotherapeutic Compass: antimycotic
antibiotics (amphotericine-B [36], nystatine [39,40], can-
didicin [37], pimaricin [30]); imidazoles (ketoconazole
[27,28,31], micozanole [57], bifonazole [58], clotrimazole
[20,22], econazole [20,22,43,49,51,52], thiabendazole [56],
tioconazole [53,55]); triazoles (fluconazole [23]); allyla-
mine (naftifin [45]) and other antimycotic (cyclopyroxo-
lamine [46,54], fluorocytosin [39], dibenzthieen [38],
buclosamide [41]).
With the exception of three studies [23,27,28] in
which the antimycotic was given orally, all others con-
cerned topical application.
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cotic and per kind of study design. For the purpose of
overview, doses and frequency are not shown; for each
study the number of patients with intertrigo in the large
skin folds is presented between brackets (the total popu-
lation studied may have been larger, if it included also
people with intertrigo in other locations or people with
other ailments).
Taken into account the weak study designs, no strong
conclusions can be drawn. It is remarkable however that
the study-authors all drew positive conclusions about
the products they studied. So one could say that there is
tentative evidence that antimycotics do work in case of
infected intertrigo and they are better than placebo
interventions. There is no basis to state that one specific
preparation is better than another, and there is no rea-
son to assert that oral antimycotics work better than
topical ones or vice versa.
Corticosteroids
In 17 studies [21,25,29,30,32,34,35,42,44,47,48,61-66]
(Additional file 4) a topical corticosteroïd was used, in
four of these as a sole intervention [21,25,61,64]. Only
one study [21] applied randomization to allocate
patients.
The mean sample size of patients with intertrigo in
the large skin folds in this group of studies was 27.7
patients (sd 33.9, min-max 7-78, median 13).
The four studies in which corticosteroids were used as
a sole intervention suggest that corticosteroids do have
some effect, and the Hedley study [21] suggests that
hydrocortisone is as effective as the combination of
hydrocortisone + miconazole. However, since there are
no placebo controlled studies, only one comparative
study, and the study populations are small, no firm con-
clusions can be drawn about the usefulness of corticos-
teroid application to intertrigo lesions.
Antibiotics
An antibiotic was applied in eight studies
[30,32,33,35,48,50,62,65]. However, in all cases the anti-
biotic was part of a combined preparation (e.g. com-
bined with a corticosteroid). So no conclusions can be
drawn about the effectiveness of antibiotics on their
own.
Antiseptics
In five studies [29,59,63,66,67] a topical antiseptic was
used, but in only one [67] as a separate intervention.
Bonnefoy et al. [67] compared eosine to the application
of cicalfate in symmetrical lesions of the large skin folds
in 49 patients; the allocation was not randomized. The
general effectiveness was judged to be very good in 40/
49 lesions treated with cicalfate versus 31/49 treated
with eosine.
Therefore, there is insufficient evidence to draw con-
clusions about the effectiveness of antiseptics.
Combined preparations
In 18 studies [21,29,30,32-35,42,44,47,48,50,59,60,62,
63,65,66] (Additional file 5) a topical combined prepara-
tion was used. Four studies were comparative: two
[59,66] compared a combination to another combina-
tion, one [30] to an antimycotic and one other [21] to a
corticosteroïd.
The combinations usually consisted of an antimycotic
and/or a corticosteroid and/or an antibiotic and/or an
antiseptic.
The mean sample size of patients with intertrigo in
t h el a r g es k i nf o l d si nt h i sg r o u pw a s2 7 . 2p a t i e n t s( s d
32.8, min-max 2-124, median 15).
Although the study-authors claimed that the combina-
tions worked, no firm conclusions about any of the
combinations can be made due to weak research designs
and the small sample sizes.
Placebo interventions
Six studies [20,22,36-38,68] compared an intervention to
a placebo intervention, two of the studies [20,22] were
RCTs. The mean sample size of patients with intertrigo
i nt h el a r g es k i nf o l d si nt h i sg r o u pw a s5 7 . 3p a t i e n t s
(sd 92.6, min-max 4-245, median 21.5).
The placebo intervention was the same as that used as
the basis component for the therapeutic comparison,
except for the of McMahon study[68] in which water
and soap were used as placebo intervention. The place-
bos were compared to econazole [20,22], clotrimazole
[20,22], amphotericine-B [36], candidicin [37],
dibenzthieen [38] or to water and soap with talcum
powder or with gauzes or with barrier cream or with
hydrocolloïd [68].
The Cullen study [20] contained six patients in the
placebo group, one of whom showed completed and
three others partial healing. In the Miura study [22] of
245 lesions, the improved or cured rate was 63% in the
placebo group versus 87% in the clotrimazole group vs
74% in the econazole group for patients with candida
intertrigo and 40%, 81% and 77% respectively for the
tinea cruris patients; there was a significant difference in
favor of the clotrimazole group versus the placebo
patients, but in the clotrimazole groups there was a lar-
ger drop-out rate that may have caused bias. The study
of Engel [36] compared symmetrical lesions of 25
patients, divided between placebo or amphotericine and
found that the results were equally good in both groups;
in five days of treatment all lesions were ‘clear’ or
‘almost clear’ and no sign of recurrence was found after
14 days, regardless of whether they were treated with
placebo or with the therapeutic intervention. Franks [37]
included four patients with symmetrical lesions in the
large skin folds, that were allocated to either a placebo
or candidicine; however, no results were given for the
placebo group. Gip [38] studied symmetrical lesions of
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dibenzthieen; after 2 weeks 14/18 lesions in the placebo
group showed improvement versus 16/18 in the other
group. Finally, McMahon [68] allocated symmetrical
lesions of 14 patients across five groups; evidently with
these sample sizes no differences between groups could
be found.
In all, it is remarkable in this group of placebo treat-
ments that many patients showed improvement or heal-
ing. Apparently, indifferent treatment may also have
some effect; maybe it is caused by attention given to
skin folds and or the indifferent cream.
Treatment with surgery
We found 15 studies [18,69-82] with surgical treatment.
All studies concerned women with macromastia who
underwent some kind of reduction mammaplasty. No
study compared the surgical intervention to another
intervention, but most gave figures about the preopera-
tive and postoperative prevalence of symptoms. It was
not always clear if the preoperative prevalences were
actually measured preoperatively or in a retrospective
w a y .T h em e a ns a m p l es i z ef o rt h e s es t u d i e sw a s1 3 8
patients (sd 110.4; min-max 33-406; median 90). In all
studies there was a clear finding that the percentage of
women with inframammary intertrigo decreased sub-
stantially after surgery (varying from 80 tot 100%).
Despite the fact that these studies did not compare the
intervention to another intervention or to a placebo,
they do all point in the same direction with considerable
effect in rather large populations. So there is at least
weak evidence that reduction mammaplasty helps in sol-
ving inframammary intertrigo.
Other treatments
Nine studies [16,26,60,67,68,83-86] used interventions
that could not be categorized in one of the above treat-
ments. In eight of these the intervention was solitary
a n di no n ew a si tap a r to fac o m b i n a t i o np r e p a r a t i o n .
In three [67,68,83] of these eight studies some kind of
comparison was made.
The mean sample size of these 8 studies was 17.2
patients (sd 15.3; min-max 3-49; median 11.5).
The products that were studied are melaleuca alterni-
folia (=tea tree oil) [84], tacrolimus [16], betulin [85],
mericleri salt [86], hamamelis virginiana [26], polynoxy-
lin [83], cicalfate [67], water and soap, water and soap
and talcum powder or gauze squares or barrier cream
or hydrocolloid [68].
The study-authors of the non comparative studies all
claimed an effect of their product. In the comparative
studies, cicalfate was slightly more effective than eosine
[67], while the studies of Alexander [83] and McMahon
[68] were too small in scale to find differences.
In all, the studies from this group of treatment were
very weakly designed and have too small samples to
allow some conclusion about their effectiveness.
Discussion
This systematic review included no studies about the
prevention of intertrigo in the large skin folds and 68
studies about the treatment of this condition. All
included studies had a number of serious methodologi-
cal weaknesses, preventing the drawing of any firm con-
clusions about the effectiveness of the studied
interventions.
The treatments examined mostly concerned the topi-
cal application of a pharmaceutical product directed at
the treatment of superinfecting micro-organisms.
Besides these interventions, 15 studies were found about
reduction mammaplasty in women with macromastia,
and all pointed in the direction that inframammary
intertrigo is reduced by this kind of surgery. So there is
at least weak but uniform evidence that reduction mam-
maplasty helps. However, it is doubtful if inframammary
intertrigo on itself constitutes sufficient reason to per-
form such an invasive intervention.
Every review has the potential to miss relevant studies.
For example, it is entirely conceivable that more studies
were performed, but were published in journals that are
not indexed by any of the databases we checked (e.g.
Chinese articles might have been missed). Also we
haven’t searched databases with conference proceedings
or databases with ongoing trials. However, searching 13
databases covering manuscripts in many languages is
more than usual for a systematic review.
Furthermore, there is a risk that this review may be
flawed by publication bias. Perhaps more studies were
performed but that have not been published. This is
often the case with studies that have no or only nega-
tive effects. If this were to be the case, these studies
would certainly not change the mean result of no firm
evidence found in this review. Formal testing of publica-
tion bias by means of funnel plot analysis was not per-
formed since this test requires a well-defined and well-
measured effect size in all studies, which was not the
case here.
During this review, we were frequently confronted with
unclear descriptions of what study-authors meant by
intertrigo, how they diagnosed it and how they measured
healing progress. This underlines the conclusion that
intertrigo deserves more serious attention from the der-
matology field on all aspects from defining to diagnosing,
pathophysiology, prevention, treatment and evaluation.
In all, this systematic review clearly demonstrates that
intertrigo is a greatly under-researched area in
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which the review was undertaken, will again have to
base its recommendations on expert opinion and not on
research evidence.
Conclusions
T h e r ei sn oe v i d e n c ea ta l la b o u tt h ep r e v e n t i o no f
intertrigo and there is no firm evidence about its treat-
ment. The treatment of intertrigo of the large skin folds
has frequently been studied but only in very weakly
designed research. Well designed studies are needed. No
firm evidence exists as to which recommendations for a
clinical guideline can be formulated.
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